- Correction
- Open access
- Published:
Correction to: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
Cancer Cell International volume 21, Article number: 520 (2021)
The Original Article was published on 14 August 2021
Correction to: Cancer Cell Int (2021) 21:426 https://doi.org/10.1186/s12935-021-02100-w
Following the publication of the original article [1], we were notified that the affiliation of the third author was incorrect.
-
Originally published affiliation: Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
-
Corrected affiliation: Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
The original article has been corrected.
Reference
Jiang H, Xu A, Xia W, Xia X, Li P, Zhang B, Zhu K, Zhou S, Wang R. Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis. Cancer Cell Int. 2021;21:426. https://doi.org/10.1186/s12935-021-02100-w.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Jiang, H., Xu, A., Xia, W. et al. Correction to: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis. Cancer Cell Int 21, 520 (2021). https://doi.org/10.1186/s12935-021-02220-3
Published:
DOI: https://doi.org/10.1186/s12935-021-02220-3